Abstract Number: 328 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
Background/Purpose: The use of biologic therapy in psoriatic arthritis (PsA) has altered the disease course and has been shown to reduce disease activity. Data comparing…Abstract Number: 329 • 2013 ACR/ARHP Annual Meeting
Health-Related Quality Of Life In Early Psoriatic Arthritis In Comparison With Early Rheumatoid Arthritis. A 5-Year Follow-Up Report From The Swedish Early Psoriatic Arthritis Registry and The Swedish Early Intervention In RA Registry
Background/Purpose: Studies on early psoriatic arthritis (ePsA) are still rare and data on health related quality of life (HRQoL) in ePsA are lacking completely. To…Abstract Number: 330 • 2013 ACR/ARHP Annual Meeting
Proteomic Profiling Of Synovial Fluid For The Identification Of Psoriatic Arthritis Soluble Biomarkers
Background/Purpose: There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in patients seen in dermatology clinics. Identifying soluble biomarkers for PsA will help in…Abstract Number: 331 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Physical Function In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…Abstract Number: 332 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Disease Among Patients With Psoriatic Arthritis Compared To Ankylosing Spondylitis (retrospective cohort study)
Background/Purpose: Both patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are at increased risk of cardiovascular disease (CVD). This increased risk is in part…Abstract Number: 333 • 2013 ACR/ARHP Annual Meeting
Changes In Weight Associated With Tumour Necrosis Factor Inhibition In Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with progressive joint damage and disability. In the last 15 years, tumour necrosis factor inhibitors…Abstract Number: 334 • 2013 ACR/ARHP Annual Meeting
The Joint Effect Of Carotid Ultrasound and Preventive Cardiology Referral On Cardiovascular Risk Factor Modification in Psoriatic Arthritis Patients
Background/Purpose: Cardiovascular disease risk is elevated in psoriatic arthritis (PsA) compared to the general population. Prior studies have demonstrated suboptimal evaluation and control of modifiable…Abstract Number: 335 • 2013 ACR/ARHP Annual Meeting
Comparing Adalimumab and Etanercept As First Line Agents In Patients With Psoriatic Arthritis. Data From The Rhumadata® Clinical Database and Registry
Background/Purpose: No long term head-to-head comparative studies of anti-TNF agents in psoriatic arthritis have been published. Controversy exists over the selection of initial biologic therapy…Abstract Number: 336 • 2013 ACR/ARHP Annual Meeting
Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up
Background/Purpose: Our previous research showed that baseline characteristics would enable the sub-categorization of psoriatic arthritis (PsA) into the distinct phenotypic groups of axial and peripheral…Abstract Number: 337 • 2013 ACR/ARHP Annual Meeting
Fatigue and Work Disability In Psoriatic Arthritis
Background/Purpose: Fatigue and work disability (WD) are common in people with psoriatic arthritis (PsA). Pain and discomfort from PsA contribute to fatigue by impairing sleep…Abstract Number: 338 • 2013 ACR/ARHP Annual Meeting
Tailored Approach To Early Psoriatic Arthritis Patients: Ultrasonographic Predictors For Structural Joint Damage
Background/Purpose: To evaluate the use of musculoskeletal US as a predictor for inflammatory structural progression in psoriatic patients Methods: Measures of association (OR) were tested,…Abstract Number: 339 • 2013 ACR/ARHP Annual Meeting
The Association Between Obesity and Radiographic Progression Of Joint Damage Among Patients With Psoriatic Arthritis
Background/Purpose: The prevalence of obesity among patients with psoriatic arthritis (PsA) is increased compared to the general population. Obese patients with PsA tend to respond…Abstract Number: 300 • 2013 ACR/ARHP Annual Meeting
Higher Disease Activity In Psoriatic Arthritis Is Associated With Elevated Total Cholesterol and Triglycerides
Background/Purpose: Psoriatic Arthritis (PsA) is linked to both obesity and an increased cardiovascular risk. However, the relationship between PsA disease activity and lipids, a major cardiovascular…Abstract Number: 301 • 2013 ACR/ARHP Annual Meeting
Arthritis and Nail Involvement In Patients With Plaque-Type Psoriasis
Background/Purpose: Psoriasis is a chronic disease that presents in individuals of all ages, affecting skin, nails and joints. Nail changes are estimated to be present…Abstract Number: 302 • 2013 ACR/ARHP Annual Meeting
Maintenance Of Efficacy and Safety Of Ustekinumab In Patients With Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy: 1‑year Results Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Background/Purpose: Ustekinumab (UST) has demonstrated substantial efficacy and an acceptable safety profile, and is approved for use, in treating moderate-to-severe psoriasis. UST has also demonstrated…